What it is
Nicotinamide mononucleotide (NMN) is involved in the body's production of NAD+. Research on NAD-related compounds asks two different questions: does the intervention change these metabolites, and does that change improve a health outcome? The systematic review below separates those outcomes.
US status: what changed
The FDA response in docket FDA-2023-P-0872, page 25 reverses the earlier conclusion that NMN was excluded from the dietary-supplement definition. This corrects our previous summary. FDA does not approve dietary supplements before they go on sale; this decision is not an approval of an NMN product or an anti-aging claim.
What human trials actually show
- Study
- Yoshino et al., 2021
- Who took part
- Postmenopausal women with prediabetes and overweight or obesity.
- Design
- 10-week randomised, double-blind, placebo-controlled trial.
- Reported result
- Muscle insulin sensitivity and insulin signalling increased after NMN supplementation; these changes were not observed after placebo.
- Limit
- A metabolic finding in this population does not establish longer life or the same effect in healthy younger adults.
What the wider review found
A 2026 systematic review included 33 human intervention studies and 80 rodent studies, with a search covering January 2010 to October 2025. Across human studies of oral NMN and NR, NAD-related metabolites changed, but functional, metabolic and vascular outcomes were mixed or specific to individual endpoints. The authors judged clinical effectiveness for anti-aging and wellness inconclusive. This is a dated review, not a claim that every later study has been assessed.
How it compares to NR
NMN and nicotinamide riboside (NR) are different NAD+ precursors. To compare the selected human studies, their populations and measured endpoints, read NMN vs NR: human research. A regulatory distinction does not establish which substance has a better health effect.
Questions and answers
Does NMN raise NAD-related metabolites in humans?
The 2026 systematic review reports biochemical effects in human studies of oral NMN and NR. A biomarker change is different from improved function or longer life.
Does the 10-week NMN trial show that it slows aging?
No. It investigated metabolic function in postmenopausal women with prediabetes, not lifespan or reversal of aging.
Is NMN excluded from US dietary supplements?
FDA's response in docket FDA-2023-P-0872 reverses the earlier drug-preclusion conclusion: NMN is not excluded from the dietary-supplement definition. This is not FDA approval of a finished product or its health claims.